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ABSTRACT
Full-length HER2 oncoprotein and splice variant Delta16 are co-expressed in 
human breast cancer. We studied their interaction in hybrid transgenic mice bearing 
human full-length HER2 and Delta16 (F1 HER2/Delta16) in comparison to parental 
HER2 and Delta16 transgenic mice. Mammary carcinomas onset was faster in F1 
HER2/Delta16 and Delta16 than in HER2 mice, however tumor growth was slower, 
and metastatic spread was comparable in all transgenic mice. Full-length HER2 
tumors contained few large vessels or vascular lacunae, whereas Delta16 tumors 
presented a more regular vascularization with numerous endothelium-lined small 
vessels. Delta16-expressing tumors showed a higher accumulation of i.v. injected 
doxorubicin than tumors expressing full-length HER2. F1 HER2/Delta16 tumors with 
high full-length HER2 expression made few large vessels, whereas tumors with low 
full-length HER2 and high Delta16 contained numerous small vessels and expressed 
higher levels of VEGF and VEGFR2. Trastuzumab strongly inhibited tumor onset in 
F1 HER2/Delta16 and Delta16 mice, but not in full-length HER2 mice. Addiction of 
F1 tumors to Delta16 was also shown by long-term stability of Delta16 levels during 
serial transplants, in contrast full-length HER2 levels underwent wide fluctuations. 
In conclusion, full-length HER2 leads to a faster tumor growth and to an irregular 
vascularization, whereas Delta16 leads to a faster tumor onset, with more regular 
vessels, which in turn could better transport cytotoxic drugs within the tumor, and to 
a higher sensitivity to targeted therapeutic agents. F1 HER2/Delta16 mice are a new 
immunocompetent mouse model, complementary to patient-derived xenografts, for 
studies of mammary carcinoma onset, prevention and therapy.
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2017
Oncotarget2www.impactjournals.com/oncotarget
INTRODUCTION
The HER2 oncogene encodes a tyrosine kinase 
involved in the onset and progression of breast cancer and 
other human tumors [1–4]. Current diagnostic and therapeutic 
criteria are based on the analysis of gene amplification and/
or protein expression as if HER2 were translated into a 
single protein species. On the contrary, tumor cells may 
contain at the same time different HER2 proteins resulting 
from mutation, alternative splicing, alternative initiation of 
translation and post-translational modification [4–15].
Some HER2 isoforms are definitely more oncogenic 
than full-length HER2 [8, 9, 16], whereas others inhibit 
carcinogenesis [12]. The Delta16 splice variant, lacking 
exon 16, has the properties of an activated oncogene [5–7, 
10, 17–20] and its expression was recently found to be 
associated with high stemness and epithelial mesenchymal 
transition [20, 21]. On the other hand, Delta16 could also play 
beneficial roles in the response to targeted therapeutic agents, 
such as the monoclonal antibody trastuzumab [18, 19].
Human breast cancers co-express Delta16 and full-
length HER2. Transgenic mice for each isoform (Delta16 
or full-length human HER2) have been developed [17, 
22], but co-expressing murine models were not studied so 
far. To study mammary carcinogenesis in a mouse model 
that mimics the human situation, we produced hybrid mice 
bearing heterozygous copies of both human transgenes (F1 
HER2/Delta16 mice), and we compared them to parental 
mice (referred to as HER2 and Delta16 transgenic mice, 
respectively).
RESULTS
Mammary carcinogenesis
Mammary carcinogenesis was slow in transgenic 
mice carrying the full-length human HER2 gene: the 
earliest mammary carcinomas appeared around 30 weeks of 
age, tumor incidence reached 100% well beyond one year 
of age (Figure 1A). In contrast, the Delta16 isoform induced 
a much faster carcinogenesis, with early tumors appearing 
around 10 weeks of age and tumor incidence reaching 
100% at 32 weeks of age. These data confirm previously 
reported tumor-free survival data on HER2 and Delta16 
mice [19]. The tumor-free survival curve of F1 HER2/
Delta16 mice overlapped that of Delta16 mice running in 
parallel (Figure 1A). To better appreciate the differences in 
mammary carcinogenesis progression of three models, we 
analyzed the number of tumors progressively appearing in 
each mouse in distinct mammary areas (tumor multiplicity). 
Delta16 and F1 HER2/Delta16 transgenic lines were 
prone to the onset of multiple primary carcinomas in 
different mammary glands with a mean of 5 and 6 tumors, 
respectively. Conversely, at the same age, HER2 mice 
developed an average of one carcinoma (Figure 1B). These 
results indicate that F1 HER2/Delta16 mice shared with 
Delta16 mice a fast mammary carcinogenesis that affected 
multiple mammary glands due to the dominant role of 
Delta16 isoform on tumor onset.
Tumor progression
After tumor onset, mammary carcinomas of HER2 
mice grew faster than those caused by Delta16, in fact 
average volume after 5 weeks of growth was about twice 
that of Delta16 mice (Figure 1C).
Delta16 mice developed more tumors than HER2 
mice (Figure 1B), but these tumors had a smaller volume 
than HER2 tumors (Figure 1C). Thus, HER2 and Delta16 
mice reached an analogous overall tumor burden at the 
same moment.
Metastatic spread of human HER2 transgenic 
mammary carcinomas, as previously found in other HER2/
neu transgenic mouse lines [23, 24], was mainly confined 
to the lungs. Lung metastases were found in about 50% 
of all mice, regardless of the transgene (Figure 1D), with 
a median time to euthanasia of 10-12 weeks from tumor 
onset in the three transgenic mouse lines.
Expression of full-length HER2 and Delta16 in 
F1 HER2/Delta16 mammary carcinomas
All mammary carcinomas of the three transgenic 
mice expressed high levels of total human HER2, 
as evaluated by means of flow cytometry and 
immunohistochemical analysis (Supplementary Figure 
1). Currently available antibodies do not distinguish the 
two isoforms, thus we used isoform-specific primers to 
measure by Real-Time PCR the expression of full-length 
HER2 and Delta16 in preneoplastic mammary glands and 
in primary mammary carcinomas.
Preneoplastic mammary glands of F1 HER2/Delta16 
mice co-expressed both isoforms at homogeneous, 
intermediate levels in comparison to mammary carcinomas 
of either full-length HER2 or Delta16 transgenic mice. 
In contrast, mammary carcinomas of F1 HER2/Delta16 
mice exhibited three alternative patterns of expression: 
tumors expressing high levels of both full-length HER2 
and Delta16, tumors expressing high levels of full-length 
HER2 and little, if any, of Delta16 and tumors with a low 
level of full-length HER2 and a high level of Delta16 
(Figure 2A). Thus, neoplastic progression to mammary 
carcinoma in F1 HER2/Delta16 mice entailed the 
activation of either or both transgenes. Individual tumors 
exhibiting different patterns of transgene expression could 
simultaneously develop within the same host (Figure 2B).
HER2 and Delta16 expressions tune tumor 
vascularization
A major difference in vascularization between 
full-length HER2 and Delta16 mammary carcinomas 
was already evident at necropsy: the former were 
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haemorrhagic, whereas the latter were generally pale. A 
microscopic study of tumor vascularization showed that 
full-length HER2 tumors mainly contained few large 
vessels or vascular lacunae (Figure 3A, 3B and 3K and 
Supplementary Figure 2), whereas Delta16 tumors were 
perfused by numerous endothelium-lined small vessels 
(Figure 3C, 3D and 3L and Supplementary Figure 
2). Mammary carcinomas of F1 HER2/Delta16 mice 
presented both types of vascularization (Supplementary 
Figure 2), however, when we classified the tumors by the 
prevalent HER2 isoform expressed (see Figure 2A), we 
found that tumors with high full-length HER2 expression 
showed few large vessels (Figure 3E and 3F), whereas 
tumors with low full-length HER2 and high Delta16 
mainly contained numerous small vessels (Figure 3I 
and 3J). It should be noted that in F1 HER2/Delta16 
tumors expressing high levels of both full-length HER2 
and Delta16 (Figure 3G and 3H) the vascular pattern 
resembled that of full-length HER2. Thus, in the vascular 
phenotype, full-length HER2 appeared to be dominant.
To investigate the molecular determinants of the 
different angiogenic patterns, we studied the expression 
of various genes involved in the control of tumor 
angiogenesis but no relevant variations (data not shown) 
were observed for several of these (FGF2, PECAM1, 
MCAM, COX2). Significant differences, mirroring the 
angiogenic patterns, were found in the tumor expression 
of vascular endothelial growth factor (VEGF) and its 
receptor VEGFR2 (KDR) (Figure 3M and 3N), which 
were higher in Delta16 and F1 HER2low/Delta16high tumors. 
Figure 1: Spontaneous mammary carcinogenesis in F1 HER2/Delta16 mice compared to parental HER2 and Delta16 
mice. (A) Kaplan-Meier tumor-free survival curves. HER2 mice n=29, Delta16 mice n=34, F1 HER2/Delta16 mice n=18. Tumor-free 
survival of HER2 mice was significantly longer (p<0.001 by the Mantel-Haenszel’s test) than that of Delta16 and F1 HER2/Delta16 
mice. (B) Tumor multiplicity. Each point represents the mean number of tumors/mouse and SEM. HER2 mice n=29, Delta16 mice n=21, 
F1 HER2/Delta16 mice n=17. By the Student’s t test (p<0.001), tumor multiplicity of Delta16 mice and F1 HER2/Delta16 mice was 
significantly higher than that of HER2 mice. (C) Kinetics of the growth of the first tumor. After 5 weeks, the average tumor dimension of 
the groups cannot be compared, because some mice with larger tumors were already euthanized, hence this would have introduced a bias 
for any further time point. Each point is the mean tumor volume and SEM. HER2 tumors n=25, Delta16 tumors n=37, F1 HER2/Delta16 
tumors n=23. By the Student’s t test the volume of HER2 tumors was significantly larger than that of Delta16 tumors (at least p<0.05 at all 
time points). (D) Autochthonous metastatic spread. Each point represents the number of lung metastases in one mouse, the horizontal bar 
represents the median. The percentage of mice with metastases are reported above each data set. HER2 mice n=23, Delta16 mice n=11, F1 
HER2/Delta16 mice n=16. By the non-parametric Wilcoxon test, no statistical difference was found in the metastatic capacity of the three 
transgenic mouse models.
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These results suggest that the angiogenic phenotype 
characterized by a high number of small vessels, typical 
of tumors expressing Delta16, was associated with higher 
cognate expression of VEGFA and of VEGFR2.
Differences in the vascular system could influence 
drug delivery to the tumor. Thus, we studied doxorubicin 
accumulation in HER2-expressing tumors (induced by 
the injection of MAMBO89 cells, established from a 
mammary carcinoma of a HER2 transgenic mouse) and 
Delta16-expressing tumors (induced by the injection of 
MI6 cells, established from a mammary carcinoma of a 
Delta16 transgenic mouse). Cell lines were used to study 
a more controlled system, with mice of the same age, 
carrying a single tumor in each mouse, induced in the 
same mammary area by the injection of tumor cells with 
a known expression of HER2 and Delta16. Spontaneous 
tumors of transgenic mice would have entailed different 
multiplicities, tumors arising in different mammary areas 
and at different ages, eventually leading to a more difficult 
interpretation of doxorubicin accumulation results.
The purpose of this experiment was to evaluate 
short-term drug accumulation. The level of doxorubicin 
in tumors, after i.v. injection, was evaluated by flow 
cytometry. Delta16-expressing tumors showed a 
significant cellular accumulation of doxorubicin as 
compared to untreated mice, whereas doxorubicin did not 
accumulate in HER2-expressing tumors (Figure 3O).
Prevention and growth inhibition of mammary 
cancer by trastuzumab
We treated F1 HER2/Delta16 mice with trastuzumab 
to analyze the sensitivity of nascent and established tumors 
to HER2 targeted therapies.
Administration of trastuzumab to full-length HER2 
transgenic mice slightly delayed tumor onset (Figure 4A). 
Figure 2: Expression of HER2 and Delta16 transcripts in mammary glands and primary mammary carcinomas. ΔCt 
represents the difference in PCR threshold cycle between the indicated HER2 isoform and reference housekeeping gene GAPDH. (A) Each 
solid point represents one tumor of HER2, Delta16 or F1 HER2/Delta16 mice; each open diamond represents one preneoplastic mammary 
gland of F1 HER2/Delta16 mice. (B) Inter-tumor heterogeneity of HER2 and Delta16 expression among individual mammary carcinomas 
arising in three mice. For each mouse tumor location is shown on the left and transcript expression in the graph on the right.
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Conversely, a long delay in mammary carcinogenesis was 
obtained with trastuzumab in Delta16 mice (Figure 4B). 
Finally, trastuzumab administration to young F1 HER2/
Delta16 mice effectively prevented mammary carcinoma 
onset (Figure 4C). At one year of age more than 85% 
of treated mice were tumor-free, whereas none of the 
untreated mice was tumor-free by 40 weeks of age.
F1 HER2/Delta16 mice are prone to develop 
multiple primary carcinomas with different HER2 
isoform levels (see Figure 2A). To investigate the effect 
of trastuzumab against homogeneous established tumors, 
we transplanted F1 HER2/Delta16 primary tumors into 
non-transgenic FVB mice. We used non-transgenic mice 
to avoid the interference with endogenous mammary 
carcinogenesis of transgenic mice even if immune 
response of non-transgenic mice could influence the effect 
of trastuzumab [25, 26]. A short (one month) treatment 
with trastuzumab strongly inhibited tumor growth for a 
long time, with more than 40% mice still tumor-free five 
months after the end of the treatment (Figure 4D). We 
analyzed the expression of full-length HER2 and Delta16 
after the treatment. No significant difference was found 
in the isoform levels between trastuzumab treated and 
untreated tumors (data not shown).
To analyze the intrinsic sensitivity of F1 HER2/
Delta16 mammary carcinoma cells to anti-HER2 
monoclonal antibody trastuzumab, we established four 
cell lines representative of three alternative patterns of 
expression found in F1 HER2/Delta16 tumors (see Figure 
2A). Cell lines of F1 HER2/Delta16 and parental origin 
were then exposed to trastuzumab in 3D (agar) cultures. A 
strong inhibition of cell growth was obtained only when 
cells expressed high levels of Delta16, either alone (MI6 
cells), or together with a low level of full-length HER2 
(F1 HER2lo/Delta16hicell lines 156-VS and 156-IS). In 
contrast, all cell lines expressing high levels of full-length 
HER2 alone (MAMBO89 cells), or together with Delta16, 
were not inhibited, regardless of the level of Delta16 
Figure 3: Different angiogenic patterns according to HER2 isoform expression. (A-J) Representative immunofluorescence 
images by confocal microscopy of primary mammary carcinomas of the strain indicated below the pictures. CD31-105 (red) and NG2 
(green) staining define blood vessels. Scale bar, 50 μm. (K-L) Area (K) and number (L) of vessels per high power field (HPF) x200. Each 
bar represents the mean and SEM of 5 ×200 fields for each tumor (n=3-5). (M-N) Expression of VEGFA (M) and KDR (N) transcripts. 
Each bar represents the mean and SEM of 3-19 tumors. ΔCt represents the difference in PCR threshold cycle between the indicated gene 
and reference housekeeping gene GAPDH. (O) Accumulation of doxorubicin in MAMBO89 (HER2hi) or MI6 (Delta16hi) tumors after 
the i.v. injection of 16 mg/kg of doxorubicin. Fluorescence intensity of doxorubicin in tumor cells was analyzed by flow cytometry and 
was expressed as fluorescence ratio between tumors of treated and untreated mice. Each bar represents the mean and SEM of 5-6 tumors. 
*=p<0.05, **=p<0.01 by the Student’s t test.
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Figure 4: Response to trastuzumab treatment in vivo and in vitro. (A-C) Prevention of autochthonous mammary carcinogenesis 
by trastuzumab treatment. Kaplan-Meier tumor-free survival curves of transgenic mice treated i.p. with vehicle (dashed line) or trastuzumab 
(solid line); statistical comparisons were made by Mantel-Haenszel’s test: HER2 mice (A) (vehicle n=8, trastuzumab n=5), no significant 
difference; Delta16 mice (B) (vehicle n=7, trastuzumab n=8), p<0.001; F1 HER2/Delta16 mice (C) (vehicle n=14, trastuzumab n=15), 
p<0.001. (D) Prevention of growth of F1 HER2/Delta16 tumors implanted in the fourth left mammary fatpad of non-transgenic FVB mice 
treated with vehicle (dashed line) (n=10) or trastuzumab (solid line) (n=9); p<0.01 by Mantel-Haenszel’s test. (E) In vitro (3D culture) 
sensitivity to trastuzumab (10 μg/ml) of cell lines derived from HER2, Delta16 and F1 HER2/Delta16 mammary carcinomas. Each bar 
represents the mean percentage (relative to vehicle-treated cells) and SEM of colonies grown in 2-4 independent experiments. MI6, 156-VS 
and 156-IS were significantly (p<0.05 by the Student’s t test) inhibited by trastuzumab. (F) Expression of HER2 and Delta16 transcripts 
in 302-IVD (upper graph) and 156-IS (lower graph) cells after trastuzumab treatment in 3D culture. Each bar represents the mean and 
SEM of 2-6 independent determinations. ΔCt represents the difference in PCR threshold cycle between the indicated gene and reference 
housekeeping gene GAPDH. A significant (p<0.01 by the Student’s t test) inhibition of both transcripts was observed only in 302-IVD cells.
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expression (F1 HER2hi/Delta16lo cell line 143-VS and F1 
HER2hi/Delta16hi cell line 302-IVD) (Figure 4E). These 
results suggested a dominant role of full-length HER2 in 
cell autonomous trastuzumab resistance.
Cells from 3D colonies grown after trastuzumab 
treatment were analyzed to quantify the expression of the 
two isoforms. 302-IVD cells, resistant to trastuzumab, 
showed a significant decrease in the level of both 
isoforms compared to cells grown without antibody. 
No change was observed in trastuzumab-sensitive 156-
IS cells. Finally, trastuzumab treatment did not affect 
the isoform ratio in both 302-IVD and 156-IS cells 
(Figure 4F).
In vivo isoform kinetics in murine and human 
mammary carcinomas
We wanted to verify whether isoform levels were 
stable in vivo in the long term. To this end we studied 
serial transplants of two F1 HER2/Delta16 mouse tumors 
in syngeneic immunocompetent hosts (mouse-derived 
isografts named MoMo1 and MoMo2) in comparison 
with two patient-derived xenografts (PDX named FO4 and 
TA18), established in our laboratory from human breast 
cancers expressing different levels of HER2, growing in 
immunodeficient NSG mice.
Serial in vivo passages of MoMo1, with a high 
expression of both isoforms, and MoMo2, with a higher 
expression of Delta16 than full-length HER2, were 
analyzed for each isoform expression by Real-Time PCR 
(Figure 5A-5B) and for the total protein level by flow 
cytometry (Figure 5C-5D): Delta16 levels were stable 
over all passages (which took more than 11 months 
in vivo), whereas the levels of full-length HER2 showed 
strong variations, including both increases and decreases 
over time (Figure 5A-5B). As shown for primary tumors 
(see Figure 3), variations in full-length HER2 and Delta16 
levels in MoMo1 and MoMo2 were accompanied by 
changes in vascularization patterns (Figure 5E-5H), thus 
indicating a functional role of HER2 isoform variations in 
tumor biology.
The same type of kinetic study performed in two 
PDX showed a remarkable stability of both full-length 
HER2 and Delta16 isoforms over the course of serial in 
vivo passages (which took more than 15 months in vivo) 
in immunodeficient NSG mice (Figure 6A). Total HER2 
protein levels, as measured by Western blot analysis 
(Figure 6B), were also stable over time.
Fragments of MoMo2 were serially implanted in 
immunodeficient NSG mice and analyzed during several 
consecutive in vivo passages. The strong fluctuations 
in HER2 expression observed in immunocompetent 
mice (Figure 5) were not present in tumors growing in 
immunodeficent mice, thus suggesting a possible role of 
the immune system in the modulation of HER2 expression 
(Supplementary Figure 3).
The level of Delta16 transcript in FO4, MoMo1 and 
MoMo2 tumors was comparable to that of prototypical 
human HER2 positive breast cancer cell line BT474 (see 
Figure 5 and Figure 6). Similarly, the level of full-length 
HER2 in BT474 was close to that of FO4 tumors, MoMo1 
original tumor and MoMo2 tumor at the fifth passage. 
TA18 tumors showed an amount of HER2 and Delta16 
transcripts lower than FO4 tumors and BT474 cell line.
DISCUSSION
One half of all human HER2 positive breast cancers 
express the Delta16 splicing isoform [10], which is thought 
to play important roles in determining cancer aggressiveness 
and response to targeted therapies [10, 17–20]. The first step 
in HER2 signaling is the dimerization of HER2 molecule 
on the cell surface. Previous studies have shown that HER2 
and Delta16 homo- and hetero-dimers are endowed with 
different activities, hence isoform interactions should 
be factored into experimental studies. However, mouse 
studies so far were performed in transgenics that exclusively 
express either full-length HER2 or Delta16 [17, 19, 22]. 
We analyzed mammary carcinogenesis, angiogenesis and 
therapeutic responses in F1 hybrid mice expressing both 
human full-length HER2 and Delta16 isoforms, to model 
isoform interactions at work in human breast cancer.
Mammary carcinogenesis was faster in F1 HER2/
Delta16 hybrid mice and a higher number of tumors 
developed in multiple mammary glands in comparison to 
mice carrying full-length HER2. The similarity between 
F1 HER2/Delta16 and Delta16 mice indicates that Delta16 
dominates carcinogenesis regardless of the presence of 
full-length HER2. Delta16 preferentially homodimerizes, 
and such homodimers are highly active [19], two facts that 
could explain the dominance of Delta16 in determining 
tumor onset.
In contrast, after tumor onset, the growth of tumors 
expressing full-length HER2 was faster than that of Delta16 
tumors, possibly as a consequence of microenvironmental 
interactions of tumor cells. We found striking differences 
in the vascularization of Delta16 and full-length HER2 
tumors. A higher expression of VEGF and its receptor 
VEGFR2 was found in Delta16 tumors, characterized 
by a more homogeneous vascular architecture based on 
numerous small vessels. In contrast, full-length HER2 
tumors contained enlarged vessels and vascular lacunae, 
which could favor a faster tumor growth and dissemination. 
Vascularization of F1 HER2/Delta16 tumors showed both 
types of patterns found in parentals, proportional to HER2 
and Delta16 levels. Concordant association between 
high HER2 expression and atypical vessels was found in 
human breast cancer [27, 28]. Our data suggest a dominant 
role of full-length HER2 as the driver of an abnormal 
vascularization. Our results warrant a future study of human 
breast cancer vascularization in relation to HER2 isoform 
expression.
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Figure 5: Kinetics of HER2 and Delta16 expression and vascular pattern in serial transplants (mouse-derived isografts, 
MDI) of F1 HER2/Delta16 mammary carcinomas. MDI MoMo1 (A, C, E, G) and MDI MoMo2 (B, D, F, H). A-B. Expression 
of HER2 and Delta16 transcripts by Real-Time PCR; ΔCt represents the difference in PCR threshold cycle between the indicated HER2 
isoform and reference housekeeping gene mTBP. C-D. Total surface HER2 protein by FACS analysis. E-H Area E-F and number G-H 
of vessels were measured by CD31 immunostaining of tumors; each bar represents the mean and SEM of 4×200 fields for each tumor. 
Student’s t test: (E) and (H), p<0.001; (F) and (G), p<0.01.
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Previous studies, including our own [10, 18, 19], 
showed that in vitro invasiveness and lung colonization 
after intravenous injection of cultured cells expressing 
full-length HER2 were lower than those of Delta16 
expressing cells. In addition Turpin and colleagues [20] 
reported an increased number of lung metastases in an 
inducible Delta16 transgenic mouse model, with an 
extremely short latency period, respect to HER2 mice. 
Figure 6: Kinetics of HER2 and Delta16 expression in serial transplants of human breast cancer patient-derived 
xenografts (PDX) FO4 and TA18. (A) Expression of HER2 and Delta16 transcripts by Real-Time PCR; ΔCt represents the difference 
in PCR threshold cycle between the indicated HER2 isoform and reference housekeeping gene hTBP. For reference, the human HER2 
positive cell line BT474 was used (dashed lines) (B) Expression of total and phosphorylated HER2 proteins by Western blot in in vivo 
passages of PDX FO4 tumors. For reference, the human HER2 positive cell line BT474 was used.
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Here, we found similar numbers of autochthonous lung 
metastases in all transgenic mice, regardless of the HER2 
isoform levels. Although the time from tumor onset to 
euthanasia was similar for all three strains, the longer 
natural history of tumors in HER2 mice could increase 
the probability of metastatic spread in these mice. On 
the other hand, the higher tumor multiplicity could 
increase metastatic dissemination in Delta16 and in 
F1 HER2/Delta16 mice. In addition, whereas previous 
studies underlined the intrinsic proliferative/invasive 
disadvantage of full-length HER2 mammary carcinoma 
cells in comparison to Delta16, our results indicate 
that microenvironmental interactions, e.g. with tumor 
vasculature [29], could counterbalance this disadvantage 
by granting preferential access to the bloodstream and 
to systemic dissemination, eventually resulting in net 
metastatic diffusion of equal entity. Our conclusion on 
autochthonous metastases is consistent with clinical data 
from Mitra and colleagues who reported an increase of 
lymph nodal invasion, but not of systemic dissemination, 
in association with Delta16 expression [10]. On the 
other hand, Alajati and colleagues reported a correlation 
between a Delta16 gene signature and a poor distant 
metastasis-free survival [18]. Further studies are needed 
to solve this issue.
The expression of the Delta16 isoform was initially 
thought to be involved in resistance to HER2 targeted 
therapies. These studies were mainly performed in vitro 
with cell lines transduced with HER2 isoforms. However, 
we have recently shown that Delta16 expression is actually 
associated with an increased trastuzumab sensitivity 
of transgenic mouse tumors, and with a decreased risk 
of relapse after trastuzumab treatment in breast cancer 
patients [19]. Susceptibility to trastuzumab was also 
reported for MCF10A-Delta-HER2 cells (expressing 
Delta16 only) injected into immunodeficient mice [18]. 
In the present work, trastuzumab treatment prevented the 
onset of mammary carcinoma, showing a higher efficacy 
in the prevention of Delta16-expressing tumors with 
respect to tumors expressing only the full-length HER2 
isoform. Therefore, even in tumor prevention, expression 
of the Delta16 isoform conferred a higher sensitivity to 
trastuzumab. We found that HER2 expression could also 
confer a lower susceptibility to cytotoxic drugs through 
limited drug accumulation due to a more irregular 
vascularization. Furthermore, in vitro we evidenced an 
intrinsic trastuzumab susceptibility of Delta16-expressing 
cells, with low or absent HER2. We and other reported a 
strong activation of Src associated to Delta16 expression 
[10, 17, 19, 30] and we reported that a high level of Src 
activation correlated with a better prognosis for patients 
treated with trastuzumab in adjuvant therapy. Moreover 
the high level of homodimers in Delta16-expressing cells 
[17, 19] could explain the strong activity of trastuzumab 
in presence of Delta16 [31].
The natural history of HER2 tumors can only be 
inferred by patients’ data. Even if HER2 is a driver of 
mammary carcinogenesis, its expression was found in 
ductal carcinoma in situ (DCIS), but can decrease in 
invasive tumors [32–34]. Furthermore, discordance 
in HER2 expression and drug susceptibility between 
primary tumors and metastases has been reported [35, 
36], thus suggesting variation in HER2 expression 
during tumor progression. Our results in F1 HER2/
Delta16 mice show that the two HER2 isoforms can 
undergo independent fates. We found a remarkable 
long-term stability of Delta16 expression during several 
months of serial transplants of F1 transgenic mammary 
carcinomas, vis-à-vis considerable fluctuations of 
full-length HER2. These results suggest that Delta16 
expression was constrained by its driver role in this 
tumor system, whereas full-length HER2 could freely 
fluctuate because it played a lesser role. It should be 
noted that a measure of the total HER2 protein levels 
with a monoclonal antibody basically mirrors the 
variations in full-length HER2, but gives no information 
on Delta16 expression, thus suggesting that only an 
assessment of HER2 isoforms could provide a reliable 
estimate of the functionally relevant oncoproteins in 
human breast cancer.
At variance with isografts in immunocompetent 
mice, patient-derived xenografts in immunodeficient 
mice did not show variations in the levels of HER2 
and Delta16 isoforms during serial in vivo passages. 
The presence of a fully-functioning immune system 
could play a role in determining the variation of the 
full-length HER2 isoform in immunocompetent mice 
offering the opportunity to investigate the different 
immunogenicity of the isoforms. PDX are now 
proposed as the best model to study new therapies since 
PDX maintain the main features of a patient’s tumor, 
including the intratumoral heterogeneity. We advocate 
the need to integrate data from PDX models with 
the study of genetically-modified immunocompetent 
tumor models, such as the new model of transgenic 
F1 mice co-expressing HER2 and Delta16 isoforms 
described here.
The study of the natural history of tumors in F1 
HER2/Delta16 mice showed that, even in genetically 
identical mice, a divergent evolution can occur, leading 
to tumors with a variable expression of HER2 isoforms, 
remindful of the human situation.
In conclusion, we showed that co-expression of 
HER2 and Delta16 isoforms tunes tumor onset, growth, 
vascularization and sensitivity to targeted therapy. Our 
results suggest that prospective clinical studies including 
a quantitative evaluation of full-length HER2 and 
Delta16 could improve the prediction of breast cancer 
sensitivity and resistance to cytotoxic and HER2 targeted 
therapies.
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MATERIALS AND METHODS
HER2 transgenic mice and autochthonous 
mammary carcinomas
Human HER2 transgenic mice [22], here referred 
to as HER2 mice, were obtained from Genentech (South 
San Francisco, CA, USA) and bred in our animal facilities. 
Human Delta16 transgenic mice [17] are here referred to as 
Delta16 mice. Delta16 male mice and HER2 female mice 
were crossed to obtain a double transgenic human HER2/
Delta16 progeny, here referred to as F1 HER2/Delta16 
mice. Female mice were monitored weekly by palpation and 
tumor dimensions were measured with calipers. Masses with 
a mean diameter exceeding 3 mm were considered tumors. 
Mice were euthanized when tumor burden was equivalent to 
10% of body mass. Tumor volume was calculated as (π/6)
(√ab)3, where a = maximal tumor diameter and b = maximal 
tumor diameter perpendicular to a. At necropsy, tumor 
masses were collected for gene expression and histological 
analysis. Non-neoplastic mammary glands were collected 
from 5-week-old F1 HER2/Delta16 mice. Lungs were 
perfused with black India ink to outline metastases, and 
fixed in Fekete’s solution. Lung metastases were counted 
under a dissection microscope. All in vivo experiments were 
approved by the institutional review board of the University 
of Bologna, authorized by the Italian Ministry of Health and 
done according to Italian and European laws and guidelines.
Mouse-derived isograft (MDI) model
Fragments of F1 HER2/Delta16 mammary tumors 
were serially implanted in the fourth left mammary fatpad of 
5-17–week–old HER2 transgenic female mice and 5-8-week-
old NOD-SCID-Il2rg−/− (NSG) female mice, obtained from 
The Jackson Laboratories (Sacramento, CA, USA). Tumors 
grown from serial grafts of fragments from two F1 HER2/
Delta16 tumors (here referred to as MoMo1 and MoMo2 
respectively) were harvested for molecular investigation and 
also immediately implanted into other mice.
Patient-derived xenograft (PDX) model
Two patient-derived xenografts expressing different 
HER2 levels, named FO4 and TA18, were originally 
established in our laboratory from human breast cancers 
by implantation in the fourth left mammary fatpad in 5-10 
week-old NSG female mice. The PDXs used in the present 
work were between the 1st and the 7th serial passage in 
NSG mice.
Histological and immunofluorescence analyses of 
tumor samples
Whole mounts were prepared as previously 
described [37]. Tumor samples were fixed in 10% neutral 
buffered formalin and embedded into paraffin or fixed in 
4% PFA and frozen in a cryo-embedding medium (OCT, 
BioOptica, Milan, Italy); 5 μm slides were cut and stained 
with Hematoxylin (BioOptica) and Eosin (BioOptica) 
for histological examination. For immunohistochemistry, 
slides were deparaffinized, serially rehydrated and, after the 
appropriate antigen retrieval procedure, stained with rabbit 
polyclonal anti-Human HER2 antibody (A0485, Dako 
Italia sr.l, Milan, Italy) or with anti-mouse CD31 (DIA-
310, Dianova GmbH, Hamburg, Germany), followed by the 
appropriate secondary antibody (Jackson ImmunoResearch, 
West Grove, PA, USA). Immunoreactive antigens were 
detected using streptavidin peroxidase (Thermo Fisher 
Scientific, Waltham, MA, USA) and the DAB Chromogen 
System (Dako) or the Vulcan Fast Red Chromogen (Biocare 
Medical, Concord, CA, USA). After chromogen incubation, 
slides were counterstained in Hematoxylin (BioOptica) and 
images were acquired by Leica DMRD optical microscope 
(Leica, Wetzlar, Germany). For immunofluorescence, 
4-6 μm cryostat sections were air-dried, fixed in ice-cold 
acetone for 10 min and incubated with the following 
primary antibodies: rat monoclonal anti-CD31 (550274, BD 
Pharmingen, BD Biosciences, San Jose, CA, USA) mixed 
with rat monoclonal anti-CD105 (550546, BD Pharmingen) 
and rabbit polyclonal anti-NG2 (ab5320, EMD Millipore, 
Billerica, MA, USA) followed by secondary antibodies 
conjugated with Alexa 546 and Alexa 488 (Thermo Fisher 
Scientific), respectively. The mixture of antibodies against 
CD31 and CD105 was used to increase the probability 
of staining all of the tumor endothelium [38]. The same 
secondary antibody was used because there was not the 
need of distinguishing the presence and the quantity of 
each single protein on cell surface. Image acquisition 
was performed using Zeiss LSM 510 META confocal 
microscope. The number and area of vessels were evaluated 
on the digital images of 3-5 tumors per group (5 fields per 
tumor at 200x microscope) by 2 pathologists, independently 
and in a blind fashion. Vessels area (in pixels) was evaluated 
with Adobe Photoshop by selecting vessels with the lasso 
tool and reporting the number of pixels indicated in the 
histogram window.
Cell lines
Cell line MAMBO89 was previously established 
from a mammary carcinoma of a HER2 transgenic mouse 
[39] and in our previous papers referred to as syn-HER2 
[39] or WTHER2 [19]; cell line MI6 was previously 
obtained from a mammary carcinoma of a Delta16 mouse 
[19]. We also established four cell lines from F1 HER2/
Delta16 mammary carcinomas, named 143-VS, 302-
IVD, 156-VS and 156-IS. All cell lines were cultured 
in Mammocult medium added with the recommended 
supplements (StemCell Technologies, Vancouver, Canada) 
+ 1% FBS (Thermo Fisher Scientific) and were maintained 
at 37°C in a humidified 5% CO2 atmosphere. All cell lines 
had been derived in our Laboratories in recent years and 
are currently monitored for murine origin by PCR, full-
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length HER2 or Delta16 isoform transgene expression by 
PCR and flow cytometry and the cell line-specific ratio of 
the two isoforms by Real-Time PCR.
BT474 breast cancer cell line was authenticated 
by DNA fingerprinting on the 11th November 2010 
(performed by DSMZ, Braunschweig, Germany). Cells 
were routinely cultured in Roswell Park Memorial 
Institute (RPMI) medium supplemented with 10% FBS 
and were maintained at 37°C in a humidified 5% CO2 
atmosphere. All medium constituents were purchased from 
Thermo Fisher Scientific.
RNA extraction and real-time PCR
RNA was extracted from frozen mammary glands, 
mammary tumors or cells by Trizol reagent (Thermo 
Fisher Scientific). Gene expression was analyzed by 
Real-Time PCR using Thermal Cycler CFX96 (Bio-Rad 
Laboratories, Hercules, CA, USA). Real-Time PCR was 
performed using Sso Advanced SyBR Green Supermix 
(Bio-Rad Laboratories) reagents. Evaluated target genes 
were: human HER2 and Delta16 [10]; mouse VEGF-A 
(qMmuCID0024411) and mouse VEGFR2 (KDR) 
(qMmuCID0005890) (Bio-Rad Laboratories). Mouse 
GAPDH [40], mouse TBP [41] and human TBP [41] 
were used as endogenous reference genes (indicated as 
ref gene). Gene expression was evaluated as ΔCttarget gene 
(Cttargetgene – Ctref gene).
Total HER2 protein detection
Single cell suspensions of tumor masses were 
analyzed for total HER2 expression on the membrane. 
Rat anti-mouse CD16/CD32 clone 2.4G2 antibody Fc 
block (BD PharMingen) was used to block Fc receptors 
in tumor-infiltrating leukocytes, to avoid the binding of 
mouse monoclonal antibodies through the Fc fragment 
instead of through the antigen-binding moiety. Mouse 
anti-human HER2 primary antibody, clone MGR-2, 
(Enzo Life Science, Farmingdale, NY, USA) and Alexa 
Fluor® 488-conjugated goat anti-mouse IgGs (H+L) 
secondary antibody (Thermo Fisher Scientific) were used. 
Fluorescence intensity was determined through flow 
cytometry (FACScan, Becton Dickinson), analysis was 
performed with FCS EXPRESS 4 (De Novo Software, 
Glendale, CA, USA).
Western blot analysis
Frozen tumor tissue was completely immersed 
in lysis buffer consisting of Novagen PhosphoSafe 
Extraction Reagent (EMD Millipore) plus phosphatase 
and protease inhibitors (Sigma-Aldrich, St Louis, MO, 
USA). Tissue was dissociated and homogenized by 
gentleMACS Octo Dissociator (Miltenyi Biotech GmbH, 
Bergisch Gladbach, Germany) and then incubated for 10 
minutes at room temperature. Nuclei were removed by 
centrifugation at 12,000 RCF at 4°C for 15 minutes, and 
protein concentration in the supernatants was determined 
by DC Protein Assay (Bio-Rad Laboratories) using bovine 
serum albumin as standard. Proteins were separated on 
an 8% polyacrylamide gel (20 μg of total lysate) and then 
transferred to polyvinylidene difluoride membranes (Bio-
Rad Laboratories). After blocking with PBS containing 
0.1% Tween 20 plus 5% nonfat dry milk for 1 hour at room 
temperature, membranes were incubated overnight at 4°C 
with primary antibodies diluted in blocking buffer. Anti-
c-ErbB2/c-Neu (Ab3) mouse monoclonal antibody (3B5) 
(1:1000; Calbiochem/EMD Chemicals, San Diego, CA, 
USA), anti-p-Neu (Tyr 1248)-R rabbit polyclonal antibody 
(sc-12352-R; 1:1000; Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) and anti-actin rabbit antibody (1:800; Sigma-
Aldrich) were used as primary antibodies. After incubation 
with the respective horseradish peroxidase–labeled secondary 
antibodies (Santa Cruz Biotechnology), protein presence 
was revealed by chemiluminescence reaction (LiteAblotplus 
chemiluminescence substrate; EuroClone, Milan, Italy).
Treatments with trastuzumab in vitro and in vivo
In vitro sensitivity to trastuzumab (10 μg/ml) was 
evaluated in three-dimensional cultures (0.33% soft agar 
containing the drug). Cells were seeded at 10,000 cells/well 
in 24-well plates. Colonies were counted two to three weeks 
after seeding. Cells from grown colonies were then collected 
and seeded in adherent culture for subsequent molecular 
analyses. In vivo, to study the prevention of primary tumor 
growth, HER2 mice, Delta16 mice and F1 HER2/Delta16 
mice were treated twice weekly intraperitoneally (i.p.) with 
trastuzumab (4 mg/kg) starting from 17 weeks of age for 
HER2 mice, and from 5-8 weeks of age for Delta16 and F1 
HER2/Delta16 mice. The start of the treatment was chosen 
in relation to the tumor latency of each transgenic mouse 
line. The analysis of whole mounts showed that at the start 
of treatments the mammary glands did not contain tumors 
(Supplementary Figure 4). Control mice were treated with 
physiological solution. To study the inhibition of tumor 
growth, fragments of a F1 HER2/Delta16 tumor pool (ΔCt 
HER2, 8.89; ΔCt Delta16 -0.88. Endogenous reference gene: 
GAPDH) were implanted in the fourth left mammary fat pad 
of 10-16-week-old FVB (non-transgenic) female mice (FVB/
NCrl, purchased from Charles River Laboratories, Calco, 
Como, Italy). Starting 7 days after fragments implantation, 
when tumors were not yet palpable, mice received twice 
weekly the intraperitoneal injection of trastuzumab (4 mg/
kg) for four weeks; control mice received physiological 
solution. Mice in each litter were randomly assigned to 
treatments one week before the start of treatments.
Doxorubicin accumulation in vivo
FVB mice bearing tumors induced by the injection 
of MAMBO89 or MI6 cell lines received intravenous 
injection of 16 mg/kg doxorubicin. Mice were euthanized 
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2 hr after doxorubicin injection and tumors were 
dissociated mechanically and enzymatically. Tumor cell 
suspensions were then analyzed by flow cytometry for 
doxorubicin fluorescence.
Statistical analysis
Tumor-free survival curves were compared using 
the Mantel-Haenszel test. All other comparisons were 
performed with the Student’s t test and Wilcoxon and 
Mann-Whitney non-parametric tests.
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